× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

SURMOUNT: Symposium review

Key messages

  • Tirzepatide is a multi-functional peptide that binds to both GIP and GLP-1 receptors.
  • 97.7% of tirzepatide patients in SURMOUNT-1 lost weight, with over a third losing at least a quarter of their initial body weight.
  • All prespecified cardiometabolic measures also improved with tirzepatide compared to placebo.
  • The tolerability and safety profiles were consistent with other injectable, incretin-based therapies.